Christopher Kim - May 13, 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role
Chairman and CMO, Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Stock symbol
APUS
Transactions as of
May 13, 2025
Transactions value $
$50,359
Form type
4
Date filed
5/15/2025, 06:48 PM
Previous filing
May 8, 2025
Next filing
May 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kim Christopher Chairman and CMO, Director C/O APIMEDS PHARMACEUTICALS US, INC., 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 2025-05-15 0002040022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APUS Common Stock, par value $0.01 per share Purchase $36K +19.8K $1.82 19.8K May 13, 2025 Direct F1, F2
transaction APUS Common Stock, par value $0.01 per share Purchase $14.4K +7.73K +39.1% $1.86 27.5K May 14, 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2)-(3) to this Form 4.
F2 These shares were sold in multiple transactions at prices ranging from $1.75 to $1.86, inclusive.
F3 These shares were sold in multiple transactions at prices ranging from $1.84 to $1.89, inclusive.